<DOC>
	<DOCNO>NCT00246103</DOCNO>
	<brief_summary>This Phase I dose escalation trial escalate dos Valproic acid one dose escalation step epirubicin . VPA escalate start dose recommend use anti-convulsant treat migraine headache . Epirubicin give infusion day 3 last dose divalproex . The study determine high dose two drug give together part multidrug regimen 5-fluorouracil cyclophosphamide .</brief_summary>
	<brief_title>Phase I Trial Valproic Acid Epirubicin Solid Tumor Malignancies</brief_title>
	<detailed_description>This Phase I dose escalation trial escalate dos Valproic acid one dose escalation step epirubicin . VPA escalate start dose recommend use anti-convulsant treat migraine headache . Recommended concentration seizure control 15-60 mg/kg . Pharmacokinetic study healthy volunteer patient suggest linear increase plasma concentration . A daily dose 16 mg/kg divalproex ( delayed-release VPA ) result peak VPA plasma concentration 127 μg/ml ( ~0.9 mM ) 27 . The recommended Phase II dose VPA 60 mg/kg/d give one-hour intravenous infusion twice daily 5 day every three week . Synergistic activity VPA epirubicin observe 0.5 mM VPA preclinical laboratory study . Patients receive intravenous load dose VPA follow divalproex two daily dos 5 dos . The load dose VPA avoid delay peak plasma concentration excessive nausea . Epirubicin give infusion day 3 last dose divalproex . Once MTD two drug regimen determine , maximum tolerate dose determine part FEC regimen ( 5-fluorouracil , epirubicin cyclophosphamide ) .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Patients must cytologically/histologically document solid tumor malignancy Age &gt; 18 year old Patients must ECOG performance status 02 Patients must able give informed consent able follow guideline give study The patient major impairment hematological function , define follow laboratory parameter : WBC &gt; 3.0x109/L ; ANC &gt; 1.5 x 109/L ; Hgb &gt; 9.0g/dL ; PLT &gt; 100x109/L ( untransfused ) . Red blood cell transfusion repeat evaluation study entry allow All patient reproductive potential must use effective method contraception study six month follow termination treatment . ( Not applicable patient bilateral oophorectomy and/or hysterectomy female patient older 50 year menstrual cycle one year . Patients must measurable evaluable disease stag study perform within 4 week enrollment ( evaluable disease refers ovarian cancer elevate CA125 prostate cancer elevate PSA ) Once MTD VPA epirubicin reach , trial limit patient breast cancer At MTD VPA FEC MTD trial expand 15 patient advanced ( inflammatory , Stage &gt; IIIB regional stage IV ) metastatic breast cancer . Patients must biopsiable disease willing undergo pre postVPA biopsy cycle 1 ; Patients must measurable disease , Patients last cohort may include biopsied Patients may cumulative anthracycline exposure great doxorubicin 300 mg/m2 epirubicin 600 mg/m2 . Patients must evidence significant active infection ( e.g. , pneumonia , cellulitis , wound abscess , etc . ) time study entry . Patients must adequate renal normal hepatic function ( creatinine &lt; 1.5 x upper limit normal ( ULN ) , bilirubin SGOT ( AST ) , SGPT ( ALT ) within 1.5 x upper institutional normal limit ) obtain within 4 week prior registration . Pregnant breast feed woman exclude study effect fetus unknown may risk increase fetal wastage . Women childbearing age must negative pregnancy test willing use highly effective method contraception . Men sexually active must also willing use accept effective method contraception . Patients take antiarrhythmic medication history cardiac failure ejection fraction £ 50 % exclude . Patients history long QT syndrome exclude study . Patients history ventricular tachycardia fibrillation also exclude . Patients must normal sinus rhythm normal PR QT interval EKG . Patients uncontrolled CNS metastasis history seizure exclude . Patients stable CNS metastasis ( either surgically resect , treat gamma knife stable 3 month follow WBRT eligible ) Patients stable brain metastasis need MRI within 4 week prior start therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Valproic Acid</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Malignancies</keyword>
</DOC>